Prediction: These Could Be the Best-Performing Value Stocks Through 2030

Motley Fool01-08 17:48

D.R. Horton should have strong growth prospects with the ongoing U.S. housing shortage. Moderna's pipeline could enable it to return to the winning ways of a few years ago. Pfizer could ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2501442587?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-08 17:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501442587","market":"us","top_or_hot":-1,"title":"Prediction: These Could Be the Best-Performing Value Stocks Through 2030","media":"Motley Fool","content":"<div>\n<p>D.R. Horton should have strong growth prospects with the ongoing U.S. housing shortage.\n\n\n\n\n\n\n\nModerna's pipeline could enable it to return to the winning ways of a few years ago.\n\n\n\n\n\n\n\nPfizer could ...</p>\n\n<a href=\"https://www.fool.com/investing/2025/01/08/prediction-these-could-be-the-best-performing-valu/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Prediction: These Could Be the Best-Performing Value Stocks Through 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrediction: These Could Be the Best-Performing Value Stocks Through 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-08 17:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2025/01/08/prediction-these-could-be-the-best-performing-valu/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>D.R. Horton should have strong growth prospects with the ongoing U.S. housing shortage.\n\n\n\n\n\n\n\nModerna's pipeline could enable it to return to the winning ways of a few years ago.\n\n\n\n\n\n\n\nPfizer could ...</p>\n\n<a href=\"https://www.fool.com/investing/2025/01/08/prediction-these-could-be-the-best-performing-valu/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PEG","symbol_name":"公务集团","start_time":0,"source_url":"https://www.fool.com/investing/2025/01/08/prediction-these-could-be-the-best-performing-valu/","article_id":"2501442587","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501442587","pubTimestamp":1736329680,"columns":[],"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"D.R. Horton should have strong growth prospects with the ongoing U.S. housing shortage.Moderna's pipeline could enable it to return to the winning ways of a few years ago.Pfizer could deliver better growth than many expect and has a head start on solid total returns thanks to its dividend.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PEG":"公务集团","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00BD4GTT62.SGD":"Legg Mason ClearBridge Infrastructure Value A SGD-H (mdis) plus","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BK4568":"美国抗疫概念","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","BK4588":"碎股","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","SG9999002232.USD":"Allianz Global High Payout USD","BK4208":"复合型公用事业","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0058720904.USD":"联博国际健康护理基金A","BK4551":"寇图资本持仓","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","BK4581":"高盛持仓","IE00BMG7P819.SGD":"Legg Mason ClearBridge - Global Infrastructure Income A Mdis SGD-H Plus","IE00BMG7P926.USD":"Legg Mason ClearBridge - Global Infrastructure Income A Acc USD","BK4504":"桥水持仓","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK4088":"住宅建筑","DHI":"霍顿房屋","BK4548":"巴美列捷福持仓","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0122379950.USD":"贝莱德世界健康科学A2","BNTX":"BioNTech SE","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE00BMG7P587.USD":"LEGG MASON CLEARBRIDGE GLOBAL INFRASTRUCTURE INCOM \"A\" (USD) INC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","PFE":"辉瑞","BK4007":"制药","BK4585":"ETF&股票定投概念","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4535":"淡马锡持仓"},"translate_title":"预测：这些可能是到2030年表现最好的价值股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PEG":1,"PFE":0.9,"BNTX":0.9,"DHI":0.9},"content_text":"D.R. Horton should have strong growth prospects with the ongoing U.S. housing shortage.\n\n\n\n\n\n\n\nModerna's pipeline could enable it to return to the winning ways of a few years ago.\n\n\n\n\n\n\n\nPfizer could deliver better growth than many expect and has a head start on solid total returns thanks to its dividend.\n\nIt might seem that valuation is no longer important for investors. Stocks that have sky-high valuation metrics continue to soar. Value stocks have lagged well behind growth stocks in recent years.Stock valuations still matter, though. Sooner or later, stocks with attractive valuations will enjoy their time in the limelight. I predict these could be the three best-performing value stocks through 2030.1. D.R. HortonD.R. Horton (DHI -1.09%) is the largest homebuilder in the U.S. based on volume -- a status it's held since 2002. The company operates in 36 states. It closed on 93,660 homes in its last fiscal year giving D.R. Horton a market share of around 14% for U.S. single-family new homes. Although its share price has jumped more than 160% higher over the last five years, D.R. Horton remains attractively valued. The stock trades below 9.9 times forward earnings. Its price-to-earnings-to-growth (PEG) ratio based on five-year earnings growth projections is a super-low 0.52, according to financial infrastructure and data provider LSEG. I think D.R. Horton's growth prospects should be exceptionally strong throughout the rest of the decade. The U.S. continues to face a severe housing shortage that can only be resolved by the construction of new homes.D.R. Horton's biggest challenge is relatively high mortgage rates and building materials costs making new homes too expensive for some families. The company has managed these issues pretty well so far, though. If rates and/or building costs decline even moderately, this stock should be a huge winner.2. ModernaModerna (MRNA 11.65%) became practically a household name during the COVID-19 pandemic. The company was one of the leaders in developing then marketing a COVID-19 vaccine. Moderna's startling speed in developing the vaccine was due to its pioneering work in messenger RNA (mRNA) vaccine and therapy development.However, Moderna's COVID-19 vaccine sales have plunged over the last few years. The positive side effect of this sell-off is that the mRNA innovator's stock is now arguably a bargain. Moderna's shares trade at around seven times forward earnings. Its enterprise value of roughly $10.7 billion is roughly 3.6 times expected 2025 sales. That's cheap no matter how you look at it. I think the worst of Moderna's COVID-19 vaccine sales slump is over. The company also now has a second approved product on the market, respiratory syncytial virus vaccine (RSV) mResvia, that could generate peak annual sales of around $1.5 billion. Investors appear to be dismissing the potential for Moderna's pipeline. I think that's a mistake. Moderna anticipates 10 product approvals through 2027. If the company comes anywhere close to that goal, it should generate significantly greater sales by the end of the decade. 3. PfizerPfizer (PFE 0.89%) was the only drugmaker to beat Moderna to market in the U.S. with a COVID-19 vaccine. The big pharmaceutical company also sells many other products, including therapies for autoimmune diseases, cancer, migraine, and more.Like Moderna, Pfizer has seen a steep decline in COVID-19 vaccine sales. It also faces the loss of patent protection for several of its top-selling drugs over the next few years. Because of these issues, its stock trades at under nine times forward earnings.However, Pfizer's growth prospects could be better than many think. The company has invested heavily in internal research and development and made multiple key acquisitions. Those efforts have added several rising stars to Pfizer's lineup, including RSV vaccine Abrysvo, migraine therapy Nurtec ODT, and cancer drugs Adcetris and Padcev. Pfizer also has a nice head start on delivering a double-digit percentage total return thanks to its dividend. The company's forward dividend yield currently stands at 6.4%.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2501442587"}